Mutations in DEPDC5 are causal factors for a broad spectrum of focal epilepsies, but the underlying pathogenic mechanisms are still largely unknown. To address this question, a zebrafish depdc5 knockout model showing spontaneous epileptiform events in the brain, increased drug-induced seizure susceptibility, general hypoactivity, premature death at 2-3 weeks post-fertilization, as well as the expected hyperactivation of mTOR signaling was developed. Using this model, the role of DEPDC5 in brain development was investigated using an unbiased whole-transcriptomic approach. Surprisingly, in addition to mTOR-associated genes, many genes involved in synaptic function, neurogenesis, axonogenesis, and GABA network activity were found to be dysregulated in larval brains. Although no gross defects in brain morphology or neuron loss were observed, immunostaining of depdc5 À/À brains for several GABAergic markers revealed specific defects in the fine branching of the GABAergic network. Consistently, some defects in depdc5 À/À could be compensated for by treatment with GABA, corroborating that GABA signaling is indeed involved in DEPDC5 pathogenicity. Further, the mTOR-independent nature of these neurodevelopmental defects was demonstrated by the inability of rapamycin to rescue the GABAergic network defects observed in depdc5 À/À brains and, conversely, the inability of GABA to rescue the hypoactivity in another genetic model showing mTOR hyperactivation. This study hence provides the first in vivo evidence that DEPDC5 plays previously unknown roles apart from its canonical function as an mTOR inhibitor. Moreover, these results propose that defective neurodevelopment of GABAergic networks could be a key factor in epileptogenesis when DEPDC5 is mutated.
In Brief
Swaminathan et al. show, using a zebrafish model lacking the mTORinhibitory epilepsy-associated factor Depdc5, that it regulates fine aspects of GABAergic network development. Further, they show that this role of Depdc5 in neuronal development is independent of its mTOR-regulatory function.
SUMMARY
Mutations in DEPDC5 are causal factors for a broad spectrum of focal epilepsies, but the underlying pathogenic mechanisms are still largely unknown. To address this question, a zebrafish depdc5 knockout model showing spontaneous epileptiform events in the brain, increased drug-induced seizure susceptibility, general hypoactivity, premature death at 2-3 weeks post-fertilization, as well as the expected hyperactivation of mTOR signaling was developed. Using this model, the role of DEPDC5 in brain development was investigated using an unbiased whole-transcriptomic approach. Surprisingly, in addition to mTOR-associated genes, many genes involved in synaptic function, neurogenesis, axonogenesis, and GABA network activity were found to be dysregulated in larval brains. Although no gross defects in brain morphology or neuron loss were observed, immunostaining of depdc5 À/À brains for several GABAergic markers revealed specific defects in the fine branching of the GABAergic network. Consistently, some defects in depdc5 À/À could be compensated for by treatment with GABA, corroborating that GABA signaling is indeed involved in DEPDC5 pathogenicity. Further, the mTOR-independent nature of these neurodevelopmental defects was demonstrated by the inability of rapamycin to rescue the GABAergic network defects observed in depdc5 À/À brains and, conversely, the inability of GABA to rescue the hypoactivity in another genetic model showing mTOR hyperactivation. This study hence provides the first in vivo evidence that DEPDC5 plays previously unknown roles apart from its canonical function as an mTOR inhibitor. Moreover, these results propose that defective neurodevelopment of GABAergic networks could be a key factor in epileptogenesis when DEPDC5 is mutated.
INTRODUCTION
Focal seizures, which originate in one part of the brain, are the most prevalent type of epileptic seizures, and mutations in DEPDC5 (Dishevelled, Egl-10, and Pleckstrin [DEP] domaincontaining 5) account for 12%-37% of cases [1] . Although numerous ion-channel mutations have been traditionally associated with epilepsy, recent work using whole-genome/exome sequencing has identified other pathways in epilepsy, such as mTOR (mechanistic target of rapamycin) signaling. The causative gene for familial focal epilepsy with variable foci (FFEVF) remained unknown until the identification of DEPDC5 mutations in a large number of families with FFEVF [2] [3] [4] . Mutations in DEPDC5 leading to haploinsufficiency have been associated also with other focal epilepsies, including autosomal dominant nocturnal frontal lobe epilepsy and familial temporal lobe epilepsy [3, 5] .
DEPDC5, along with NRPL2 and NRPL3, forms the mTORinhibitory GATOR1 complex, which blocks the activation of the classical mTOR complex mTORC1 when amino acid concentration is low [6] . Mutations in all three components have been linked to focal epilepsy with/without cortical malformations [7] [8] [9] [10] . The mTOR pathway plays a significant role in the regulation of protein synthesis and in critical cell-fate decisions such as autophagy. Absence of regulation of this pathway results in constitutively high mTORC1 activity, and mTOR hyperactivation has been implicated in various neurological conditions associated with intractable seizures [11] . Thus, mTOR inhibitors such as rapamycin and its analogs hold significant potential in anti-epileptogenic therapies [12, 13] .
Because the components of the GATOR1 complex have only recently been associated with epilepsy, their pathophysiological roles related to focal epilepsy are yet to be completely understood. Moreover, some initial discoveries found that multiple DEPDC5 mutations in patients are located in a domain of unknown function (DUF3608) [3] , thus suggesting that unexpected roles of DEPDC5 may be associated with its pathogenicity. There are three rodent models of DEPDC5 knockout, where homozygotes show mTOR hyperactivation, severe morphological defects, and premature death [14] [15] [16] . The conditional knockout mouse model reported recently describes cortical defects and increased seizure susceptibility in adult mice, recapitulating many features of mTORopathies [16] . However, in order to investigate the function of DEPDC5 during neurodevelopment, new animal models more conducive to the study of early development are required, and hence we used zebrafish as a handy neurodevelopmental model.
In this study, we report the generation and use of a zebrafish model of DEPDC5 loss of function to understand the underlying pathological mechanisms. This depdc5 knockout model showed mTOR hyperactivation, behavioral hypoactivity, spontaneous epileptiform brain events, increased drug-induced seizure susceptibility, and premature death. An unbiased transcriptomic analysis of the brains of depdc5 À/À larvae was performed that showed that, apart from the metabolic perturbation occurring due to mTOR hyperactivation, the regulation of neurodevelopmental pathways was also affected. In particular, fine branching of the GABA network was specifically affected by DEPDC5 knockout. Consistently, treatment with GABA could compensate for some of the defects. Further, these neurodevelopmental changes as well as the transcriptomic changes induced by DEPDC5 knockout occur independent of mTOR signaling. As a result, this study presents new evidence that DEPDC5 is not only involved in mTOR-dependent pathways but is also involved in previously unknown mTORindependent functions especially during neurodevelopment, a combination of which results in focal epilepsies. These novel insights into the function of DEPDC5 in brain development bring the first evidence of how DEPDC5 loss of function could lead to epilepsy.
RESULTS

Depdc5 Is Essential for Vertebrate Survival
Although DEPDC5 mutations are associated with epilepsy, the underlying pathology of this class of focal epilepsies remains unstudied. Zebrafish have only one ortholog of DEPDC5, and sequence alignment of the zebrafish and human proteins showed a high degree of conservation, with 75% identity and 84% similarity. Whole-mount RNA in situ hybridization showed that depdc5 is expressed in the forebrain, midbrain, and hindbrain and also in the neural tube and notochord during zebrafish development ( Figure 1A) .
Using CRISPR/Cas9 genome editing, the 14 th exon of depdc5, encoding DUF3608, which was initially found to be mutated in many patients [2, 17] , was targeted for disruption. A positive founder transmitting a 4-nt frameshifting deletion was selected, which would lead to the expression of a truncated protein (352 amino acids instead of the 1,568-residue wild-type protein; Figure 1B) . Quantification of mRNA expression showed a significant reduction in heterozygous and homozygous larvae ( Figure 1C ). Because crosses of heterozygotes never resulted in viable , and depdc5 À/À , was monitored for a month from 0 day post-fertilization (dpf). Whereas most of the depdc5 +/+ and +/À larvae survived for this period, all the depdc5 À/À larvae died by 2 weeks of age ( Figure 1D) . Notably, the survival of depdc5 À/À can be extended by a few days if they are separated early and raised with extra care, although they never survive after 20 dpf. However, no obvious morphological defects or changes in eye size were observed, although a small reduction in body length was seen following quantification ( Figures 1E and 1F ). Although this observation is consistent with the premature death of rodent Depdc5 À/À models [14] [15] [16] , the growth delay observed in the complete knockout rodent embryos was not evident in the case of depdc5 À/À zebrafish larvae. Hence, although vertebrates can survive haploinsufficiency of DEPDC5, total absence leads to death during development.
depdc5
-/-Larvae Show mTOR Hyperactivation, Brain
Epileptic Discharges, Hypoactivity, and Increased Seizure Susceptibility Because DEPDC5 is known to negatively regulate mTOR, mTORC1 activity was assessed through the phosphorylation state of the ribosomal protein S6, which is a downstream effector of mTORC1 [18] . Lysates of 8-dpf depdc5 +/+ , depdc5 +/À , and depdc5 À/À larvae were analyzed by western blotting using antibodies against the S6 Ser240/244 phospho-epitope, and a gradual increase in phosphorylation was observed (Figure 2A ), indicating high mTORC1 activity in the absence of DEPDC5. This was confirmed by performing immunohistological analysis, where depdc5 À/À larval brains showed greater levels of phospho-S6 ( Figure 2B ). However, no abnormal or dysmorphic cells were visible. In order to monitor epileptic activity, brain activity was monitored using non-invasive local field potential (LFP) recordings from the optic tectum [19] . Recurrent spontaneous epileptiform events were observed in depdc5 À/À larval brains at 9 dpf ( Figures 2C and 2D ) at a mean frequency of 9.1 ± 5.0 events/10 min and mean duration of 309.7 ± 152.3 ms, confirming the pathogenicity of DEPDC5 loss of function. However, because the LFPs were monitored only for 10 min, this epileptic brain activity was observed in only 9/42 larvae, and it is possible that many larvae show epileptiform discharges outside this period. Nevertheless, no such events were recorded in different batches of depdc5 +/+ (0 out of 40 larvae). It is also possible that these epileptiform discharges manifest earlier but were only monitored at 9 dpf in order to increase the chances of detecting them. The absence of epileptiform discharges in 100% of the animals is consistent with similar observations in Depdc5 conditional knockout mice and patients with focal epilepsy [16] . In order to have a more accurate readout of the abnormalities in depdc5 À/À larvae, their locomotor activity was quantified in light-dark cycles. depdc5 À/À larvae were significantly hypoactive ( Figure 2E ), and this was observed in 100% of the larvae across generations from 5 dpf onward (N > 5; n > 300), until before death. These results are also consistent with other mTORopathy zebrafish models that show epileptic brain activity and are hypoactive [20] . Interestingly, when coiling (rotating movement of the embryo inside the chorion) was monitored at 20 hr post-fertilization (hpf), this earliest motor behavior was already lower in depdc5 À/À embryos ( Figure 2F ), indicating that the hypoactivity begins very early during development, suggesting that DEPDC5 loss of function may have consequences for early neurodevelopment. Last, the susceptibility of depdc5
larvae to chemically induced seizures by pentylenetetrazol (PTZ) was tested. Consistent with what has been reported in mice [16] , depdc5 À/À larvae show a significantly increased response to PTZ (shorter delay of response to PTZ exposure and higher swimming activity) compared to their siblings ( Figures  2G and 2H) . Altogether, the phenotypes observed upon knocking out depdc5 in zebrafish are reminiscent of what is observed in the existing rodent models of Depdc5 knockout and also, to an extent, in patients. Altogether, these results validate the pathogenicity of depdc5 loss of function in zebrafish.
Alteration of Brain Gene Expression Profile in depdc5
-/-In order to obtain new, unbiased insights into the molecular perturbations occurring during neurodevelopment in the absence of DEPDC5, brains of 10-dpf depdc5 +/+ and À/À larvae were dissected out and total RNA was extracted for deep sequencing ( Figure 3A ). Table S1 ; description is provided for the top dysregulated genes). Notably, 16 out of the 20 aminoacyl-tRNA synthetases in zebrafish were upregulated in the depdc5 À/À brains, presumably due to improper mTOR regulation. Functional annotation and clustering of the significantly dysregulated genes showed that apart from aminoacyl-tRNA biosynthesis and electron transport chain activity that can be attributed to mTOR pathway dysfunction, the expression of genes involved in other pathways including chordate embryonic pattern specification, regulation of neuron projection morphogenesis/axonogenesis, synapse formation, zinc finger/transcription factors, and ion channels was also perturbed ( Figure 3B ). This suggested that DEPDC5 may also play a role in embryonic neurodevelopment.
Because genes related to neurodevelopment were altered, the number of neurons during developmental stages was analyzed. Measurement of head size and staining with cresyl violet showed that the size and morphology of depdc5 À/À larval brains were similar to those of the control ( Figures 3D and 3F ). In addition, using immunostaining against acetylated tubulin and phosphorylated histone H3 (which label neuronal fibers and mitotic (G) Distance swam by 2-dpf embryos upon exposure to 3 mM PTZ represented as fold change compared to basal distance swam by wild-type larvae at t 0 . N = 3, n > 10; Student's t test, *p < 0.05. (H) Representative swimming tracks of 2-dpf embryos during a 10-min period following a 3 mM PTZ exposure (tracks of 3 replicates are shown in rows for each genotype).
cells, respectively), the main brain networks and neurogenesis itself did not appear to be affected ( Figures 3C and 3E ). However, many genes related to GABAergic networks, which have conventionally been correlated with other kinds of epilepsy, were downregulated. Indeed, 3 GABA receptors (GABRA1, GABBR1b, and GABRG2) and other associated factors required for synthesis and transport of GABA and GABAergic synapse formation, maturation, and transmission (such as Gat3, pyruvate carboxylase, Kcc2, and neuroligin 2) were all downregulated (Table S3 ). (E) Whole-mount images of 48-hpf depdc5 +/+ and À/À larvae immunostained with a-phosphorylated histone H3 (n > 3/genotype).
(F) Cresyl violet staining comparing 7-dpf depdc5 +/+ (top half) and depdc5 À/À (bottom half) larval heads showed no gross difference in the density of cells in the brain. Scale bar, 100 mm.
Because the expression of multiple factors important for GABAergic network formation and synaptic function was perturbed, the expression of three markers of inhibitory synapses, Gad65/67, gephyrin, and neuroligin 2 (Nlgn2), was examined by immunostaining of transverse sections from 8-dpf depdc5
and depdc5 À/À larval brains. Interestingly, close examination of the sections immunostained with Gad65/67 showed that finerbranched structures were not present as in wild-type siblings ( Figure 4A ). 3D reconstruction of Gad65/67 staining confirmed that the Gad65/67 projections (in blue in Figure 4B ) are less arborized in the mutant brains (Video S1 and Video S2). Because GABA-synthetizing enzymes are expressed in clusters at the pre-synaptic GABA synapses, these results confirm defects in the GABAergic network connectivity. Immunolabeling against gephyrin and Nlgn2 also showed a significant decrease of the complexity in depdc5 À/À brains ( Figures 4C and 4D ). Upon quantifying the GAD65/67-and gephyrin-positive neurofilaments and puncta from at least three biological replicates, both were decreased by >50% in depdc5 À/À ( Figure 4F ). Last, immunolabeling and quantification of the interneuron population using parvalbumin 7 antibody did not show any difference in the number of positive cells ( Figures 4E and 4F ). These results demonstrate that DEPDC5 loss of function significantly impacts fine branching of the GABAergic network during neurodevelopment without causing major loss of interneurons.
GABA Exposure Rescues Hypoactivity and Seizure Susceptibility in depdc5 -/-Larvae through Paracrine Effects
Because the expression of GABA-synthetizing enzymes seemed to be affected, we hypothesized that exposure to GABA may compensate for this decrease and could therefore rescue the consistent hypoactivity and seizure susceptibility phenotypes of depdc5 À/À larvae. Concurrent with this hypothesis, GABA treatment could completely rescue the hypoactivity of depdc5 À/À larvae (swimming at 7 dpf and coiling at 24 hpf) ( Figures 5A and 5B). Rapamycin, which has a positive effect on other mTORopathy models, was used as a positive control, and could also completely rescue the hypoactivity of depdc5 À/À embryos and the increased phospho-S6 levels (Figures 5A-5C). Moreover, GABA treatment, as well as rapamycin, could rescue the seizure susceptibility of depdc5 À/À larvae exposed to PTZ to the level of their siblings ( Figures 5D and 5E ). Hence, these results confirm earlier observations from transcriptomic and immunolabeling experiments that GABA network/signaling is indeed altered in depdc5 À/À larvae. Moreover, it shows that both GABA and mTOR signaling are involved in the pathogenicity of depdc5 loss of function. In order to assess whether this rescuing effect could be a result of a rescue of the neurodevelopmental defects themselves, neuronal branching of GABAergic neurons was monitored following GABA treatment. However, supplementation with GABA could not rescue the fine neuronal branching defects observed in depdc5 À/À larvae (Figures 5F and 5G), thus suggesting that GABA can only compensate for, but not rescue, the neurodevelopmental defects. Further, when the effect of GABA and rapamycin treatment on larval survival was tested, GABA exposure could not rescue the premature death at 2-3 weeks post-fertilization (wpf), whereas rapamycin treatment extended the lifespan as long as it was supplemented ( Figure 5H ). This supports our conclusion that GABA exposure can only partially compensate for the neurodevelopmental defects. Hence, these results show that although increasing GABA levels could compensate for defective GABAergic branching, it could not rescue the neurodevelopmental defect itself. This also indicates that the premature death is essentially due to perturbation of mTOR signaling (which could be rescued by rapamycin), rather than the GABA network defects. Indeed, rapamycin needed to be continually supplemented, because withdrawal of rapamycin led to gradual death ( Figure 5H ), reiterating the contribution of mTOR deregulation to premature death.
In order to understand whether the compensating effect of GABA was mediated through GABA receptors or independent of them, muscimol (a GABA A receptor agonist), baclofen (a GABA B receptor agonist), and vigabatrin (an inhibitor of GABA transaminase that increases local GABA concentration) were tested for their effect on depdc5 À/À larvae ( Figure 6A ).
Interestingly, treatment with the GABA receptor agonists muscimol and baclofen and even both in combination could not rescue the hypoactivity. However, exposure to vigabatrin, which increases the endogenous GABA level by inhibiting its metabolism, completely rescued the hypoactivity of depdc5 À/À larvae as well as PTZ hypersensitivity ( Figure 6B ). This proves that GABA acts through receptor-independent mechanisms in a paracrine fashion. Moreover, the fact that inhibiting GABA metabolism using vigabatrin is sufficient to rescue the phenotype suggests that GABA itself mediates the compensating effects rather than metabolites of GABA. Altogether, these results support the idea that DEPDC5 loss of function impairs early neurodevelopment, especially GABA network fine branching, which is likely to contribute to epileptogenesis, and that mTOR-dependent metabolic changes are more generalized and severe, eventually resulting in premature death.
mTOR-Dependent and -Independent Pathways Are Perturbed in depdc5
-/-Larvae
In order to further understand whether these two phenomena, upregulation of mTOR signaling and defective development of GABAergic networks, are related and act together in the same pathway or are controlled independently by DEPDC5, the depdc5 À/À differentially expressed gene dataset was compared to datasets from three other zebrafish models of epilepsy. These included: (1) a gabra1 À/À zebrafish line recapitulating idiopathic generalized epilepsy, in which the GABAergic network is defective (E.S., unpublished data), (2) an mTORopathy epilepsy (tsc2
) zebrafish model in which mTORC1 activity is increased [20] , and (3) a Dravet syndrome zebrafish model (scn1Lab mutant carrying a mutation in Na v 1.1 [21] ), as a neutral mTORand GABA-non-related epilepsy model ( Figure 6C ).
177 genes were found to overlap between the depdc5 and gabra1 datasets (15% and 40% of the total number of genes in the depdc5 and gabra1 datasets, respectively) and, remarkably, 99% of them (175/177) showed the same trend of up-or downregulation in both datasets, suggesting specific common mechanisms. When functional clustering and annotation of the common genes were performed, these genes were found to be involved in electron transport, embryonic morphogenesis, GABA receptor activity, synapse formation, general synaptic activity, axonogenesis, nucleotide binding, and transcription ( Figure 6D ; Table S3 ). Interestingly, many factors that have been associated with epilepsy earlier were also dysregulated. This significant overlap between depdc5 and gabra1 datasets provides further evidence that DEPDC5 loss of function induces broad defects in the GABA network.
Because both DEPDC5 and TSC2 are involved in the negative regulation of mTOR, common genes between these two datasets showed mTOR-related pathways as the largest group of +/+ larvae normalized to 100%, shows that treatment with GABA (100 mM) can completely rescue hypoactivity; N = 2, n = 20/genotype/treatment. Rapamycin treatment (100 nM from day 0 to 2, 300 nM from day 3 onward) was used as a positive control.
(B) Spontaneous coiling activity in 20-hpf embryos shows that the hypoactivity of depdc5 À/À embryos is rescued by treating with 100 nM rapamycin or with 100 mM GABA from the single-cell stage. N = 2, n = 20/genotype/treatment; Student's t test, ****p(control WT versus HM) < 0.0001. Coiling activity of depdc5
was set at 100% for each sample, and the relative activity of the depdc5 À/À larvae is represented.
(C) Western blotting of 9-dpf larval lysates to examine phospho-S6 levels in depdc5 +/+ and depdc5 À/À larvae treated with DMSO or rapamycin (100 nM from day 0 to 2, 300 nM from day 3 onward) shows inhibition of mTOR signaling upon rapamycin treatment.
(D) Distance swam by 2-dpf larvae treated with GABA (100 mM) or rapamycin (100 nM) upon PTZ exposure (3 mM). N = 3, n > 10.
(E) Representative swimming tracks of 2-dpf embryos (untreated or treated with GABA or rapamycin) during a 10-min period following PTZ exposure (3 mM).
(F) Images of transverse sections of 7-dpf GABA-treated depdc5 +/+ and depc5 À/À larval brains immunostained with a-GAD65/67 and counterstained with DAPI.
Regions indicated in red boxes have been magnified to show the branching defects. GABA treatment (100 mM) was begun at 8 hpf; n = 3 embryos/genotype. Scale bar, 10 mm. genes upon functional clustering and annotation (Table S4) . About 15% of genes of the two datasets were found to be genes encoding for mTOR-related members such as aminoacyl-tRNA synthetases, stress response, and protein phosphorylation. The overlap of the depdc5 dataset with data from other models of epilepsy (Scn1Lab) and autism spectrum disorder (data not shown) did not show a significant overlap (only 23 genes in common between the depdc5 À/À and Scn1Lab À/À datasets), thus confirming the specificity of the overlaps described above. Surprisingly, among the 177 common genes between the gabra1 and depdc5 datasets that were involved in neurogenesis and GABA networks, only 18 genes were found to be in common with the tsc2 dataset. The non-overlapping nature of 90% (159 of 177) of the genes indicates that these neurodevelopment-associated genes are more likely to be unrelated to mTOR, but rather controlled by DEPDC5 independent of its canonical mTORinhibitory function. These observations show that in the absence Table S3. of DEPDC5, there are mTOR-dependent metabolic changes (which overlap with the tsc2 model) but also mTOR-independent neurodevelopment defects, especially in the GABAergic network (which overlap with the gabra1 model), a combination of which presumably leads to epilepsy.
Neurodevelopmental Defects in depdc5 -/-Larvae Are Independent of mTOR Signaling In order to confirm the independent nature of the mTOR and GABA pathways, mTOR signaling was assessed following treatment with GABA in depdc5 +/+ and À/À larvae ( Figure 7A ). Consistent with the hypothesis, GABA treatment could not rescue the increase in mTOR activity in depdc5 À/À larvae ( Figure 7A , top). Moreover, the levels of phospho-S6 were also checked in gabra1 À/À larvae, which have defective GABA signaling and it did not show any change ( Figure 7A , bottom). These results indicate that GABA and its related metabolism do not control mTOR signaling. Further, in order to confirm that the neurodevelopmental defects induced by depdc5 loss of function are indeed mTOR independent, the ability of rapamycin to rescue the fine branching of the GABAergic network in depdc5 À/À larval brains was assessed. Brain slices from rapamycin-treated depdc5 +/+ and À/À larvae were immunostained using a-GAD65/67. Rapamycin treatment failed to rescue the reduced fine branching of the GABAergic network during development in depdc5 À/À . Indeed, similar to what was observed in untreated depdc5 À/À brains (Figure 4) , the GAD65/67-positive neurofilaments were less arborized even after rapamycin treatment ( Figures 7B and 7C) , proving that the GABAergic branching defects resulting from the absence of DEPDC5 are indeed mTOR independent. Of note, phospho-S6 levels were significantly reduced when rapamycin was applied at this concentration ( Figure 7D ). To confirm the mTOR-independent effects at the molecular level, the ability of rapamycin to restore the expression of critical up-and downregulated genes back to normal was tested in order to assess whether the transcriptional changes were also mTOR independent. The genes that were chosen for testing by RT-qPCR were related to axon guidance (plxn2a, sema3b, efnb3b) and GABA synapse activity (gabrg2, gat3, kcc2), which were in common with the gabra1 dataset, and also some mitochondrial factors (mt-cyb, mt-co2). Consistent with their involvement in metabolic processes, the expression of mitochondrial +/+ and depdc5 À/À larval lysates shows no change in phospho-S6 levels upon GABA treatment (100 mM from 8 hpf; top).
Western blotting of 7-dpf gabra1 +/+ and gabra1 À/À larval lysates shows no difference in mTOR signaling upon knocking out gabra1 (bottom).
(B) Images of transverse sections of 7-dpf rapamycin-treated depdc5 +/+ and depc5 À/À larvae immunostained with a-GAD65/67 and counterstained with DAPI.
Section level is displayed in the schematic drawing. Regions indicated in red boxes have been magnified to show the branching defects. Rapamycin treatment was begun at 8 hpf: 100 nM from day 0 to 2, 300 nM from day 3 onward; n = 3/genotype. Scale bars, 10 mm.
(C) Quantification of GAD65/67-positive neurofilaments in rapamycin-treated depdc5 +/+ and À/À larval brain sections shows that rapamycin treatment does not rescue the reduced number of filaments in depdc5
Western blotting of 5-dpf larval lysates upon treatment with increasing concentrations of rapamycin (50 nM, 250 nM, 500 nM, 1 mM, and 2.5 mM) from 8 hpf to estimate phospho-S6 levels shows a dose-dependent decrease. Rapamycin-containing water was changed every day. (E) RT-qPCR-based estimation of some down-and upregulated genes involved in axon guidance, GABA synapse activity, and metabolism. ef1a expression was used for normalization; expression of depdc5 +/+ was normalized to 1 (*p < 0.05, **p < 0.01).
(F) Swimming activity of 7-dpf tsc2 larvae treated with rapamycin and GABA (day 0 onward) over 5-min light/10-min dark phases, with the activity of tsc2 +/+ larvae normalized to 100%, shows that rapamycin, but not GABA, can rescue the hypoactivity (Student's t test, ****p < 0.0001).
cytochrome B and cytochrome C oxidase II genes in depdc5
brains was decreased to wild-type level upon rapamycin treatment ( Figure 7E ). However, for the genes involved in axon guidance and GABA synapse activity, rapamycin treatment could not rescue the reduced expression observed in depdc5 À/À larval brains ( Figure 7E ). This incapability of rapamycin to rescue both the neurodevelopmental defects and the transcriptional changes proves that the molecular defects are indeed mTOR independent. Last, if GABAergic network defects induced by DEPDC5 knockout are mTOR independent, GABA would not have any effect on another genetic model of mTOR hyperactivation such as tsc2 À/À [20] . Consistently, when tested on tsc2 À/À larvae, GABA was unable to rescue the hypoactivity, again validating the mTOR-independent nature of the defects observed in depdc5 À/À larvae ( Figure 7F ). Of note, rapamycin, which was used as a positive control, could rescue the hypoactivity observed in tsc2 À/À larvae.
Hence, these results show that at the phenotypic, cellular, and molecular levels, alongside its canonical mTOR-inhibitory function, DEPDC5 does control neurodevelopmental aspects of GABAergic networks in an mTOR-independent fashion.
DISCUSSION
Mutations in the members of the mTOR-inhibitory GATOR1 complex have recently been shown to be associated with focal epilepsy [7] [8] [9] [10] . However, multiple aspects of this complex remain poorly understood, including the molecular pathways through which it plays a role in normal brain activity and/or development.
Depdc5 is strongly expressed in the developing vertebrate nervous system as shown by in situ hybridization of early zebrafish embryos, indicating a role for this protein in neuronal development. DEPDC5 is expressed specifically in neurons in the human brain (see Human Protein Atlas Database [https://www. proteinatlas.org/ENSG00000100150-DEPDC5/cell] and Human Brain Transcriptome Project [http://hbatlas.org/hbtd/images/ wholeBrain/DEPDC5.pdf]), where the transcript was first identified [2, 22] , but this is the first report showing its strong expression in the developing vertebrate neural system.
In order to understand the role of DEPDC5 in neurodevelopment and brain activity, the first zebrafish knockout model of depdc5 was generated and studied. Although rodent models have been recently generated [14] [15] [16] , the zebrafish model proffers specific technical advantages for studying early neurodevelopment. Although depdc5 À/À zebrafish larvae do not show obvious phenotypic changes, they exhibit transient spontaneous epileptiform discharges in their brain and increased seizure susceptibility before they die prematurely at about 2 wpf. The zebrafish model also proffers a platform for drug-screening purposes. Our zebrafish model would be convenient for initial highthroughput drug-screening assays that could identify candidate molecules restoring the depdc5 À/À larval phenotype (i.e., hypoactivity and seizure susceptibility) and later be confirmed in mammalian models. Such an approach using complementary vertebrate models has proven to be effective and time saving in identifying new therapeutics for other genetic diseases [23] . Hypoactivity and seizure susceptibility of the larvae were consistently observed and could be used as an accurate readout for further studies. It is noteworthy that another zebrafish model with hyperactive mTOR owing to mutated tsc2 also shows hypoactivity and premature death along with epileptic seizures [20] . Also, because the hypoactivity is observed from very early on, coiling could also be used as a readout in drug screening to economize on time. Notably, no enlarged or abnormal cells were detected in the developing zebrafish brains in this model. This could be explained by the ''two-hit'' hypothesis, where an additional hit along with DEPDC5 mutations occurs to cause focal cortical dysplasia (FCD) in patients [9] . Also, although depdc5 À/À larvae show considerably lower mRNA levels, it was not completely absent, probably due to incomplete degradation of depdc5 mRNA by nonsense-mediated decay. However, the significant reduction of mRNA levels shows that the phenotypes observed were a result of haploinsufficiency.
With the aim of gaining further insights into the molecular perturbations in epileptic depdc5
À/À brains, transcriptomic analysis was performed in this study, which showed interesting candidates that were up-or downregulated. This is the first report of an in vivo transcriptomic profile from a model of a dysfunctional GATOR1 complex. As expected, various mTOR-regulated pathways such as amino acid metabolism were upregulated owing to mTOR deregulation, including most aminoacyl-tRNA synthetases. Although loss-of-function mutations in some aminoacyltRNA synthetases have been shown to be associated with epilepsy [24] [25] [26] [27] , the contribution of such a broad upregulation in expression levels of these factors to epilepsy remains to be understood. Interestingly, although factors associated with neurogenesis, axonogenesis, and synaptic functions were downregulated, rather than gross morphological defect or neuron loss, specific downregulation of GABA receptors, transporters, and factors involved in inhibitory network development, synapse formation, and function was observed, revealing for the first time the possible role of DEPDC5 in the formation, pruning, and maintenance of the GABAergic system. GABA exposure could partially compensate the phenotype observed in depdc5 À/À larvae. The use of GABA receptor agonists in mTORopathies has been explored only for tuberous sclerosis complex (TSC) [28] , but muscimol and baclofen were ineffective in depdc5 À/À larvae. These observations suggest that the compensating effect of GABA is more likely to be a paracrine effect of GABA rather than through GABA receptors. In this context, the ability of vigabatrin to rescue the phenotype also confirms the direct effect of GABA rather than of its metabolites. Notably, GABA can only partially ameliorate the depdc5 À/À phenotype, and therefore cannot be considered as a candidate drug against refractory epilepsies. However, the observation that GABAergic networks are affected early during development in a vertebrate DEPDC5 knockout model is an important consideration for treatment strategies. Indeed, it might be useful to design therapeutic strategies that can restore or at least compensate stably the neurodevelopmental defects, rather than solely trying to treat symptomatically, i.e., alleviate the seizures. Notably, the paracrine effect of GABA observed here is also significant, because many patients with mutations in DEPDC5 are refractory to conventional anti-epileptic drugs, which generally act through GABA receptors such as benzodiazepines. Thus, the application of molecules that would increase GABA signaling independent of GABA receptors (such as vigabatrin) could be interesting in the context of these refractory epilepsies. Predictably, rapamycin could rescue the phenotype, and also prevent premature death, suggesting that mTOR deregulation affects multiple organismal functions. Rapamycin and rapalogs have proved to be extremely effective against many mTORassociated diseases including cancer, lymphangioleiomyomatosis (LAM), and tuberous sclerosis [29] [30] [31] . Rapamycin has also been shown to extend longevity and have neuroprotective effects [32, 33] . Like in earlier studies with other diseases, although very effective, cessation of rapamycin treatment led to reappearance of the symptoms and death [30, 34] . Due to various reasons including activation of alternate or compensatory pathways, rapamycin treatment has had modest outcomes in clinical trials despite very promising pre-clinical animal model studies [35] . Hence, rapamycin and rapalogs are now being tested for combination therapy as chemotherapeutic agents, and these could also be applied to treat focal epilepsies, as there is a need to identify new targetable mechanisms of focal epilepsy in order to design new drugs against refractory seizures.
Through multiple comparisons of transcriptomic datasets, a large set of genes from the depdc5 dataset was found to overlap with the gabra1 dataset independent of the tsc2 dataset, suggesting that DEPDC5 has unexpected mTOR-independent activity, especially in regulating GABA network development, as proven experimentally (Figure 7 ). Hence, it is possible that the two inhibitory complexes, GATOR1 (via DEPDC5) and TSC, play distinct roles in different pathways and cell types in addition to their overlapping mTOR-related functions. DEPDC5 function is still incompletely understood, and many epileptic mutations have been identified in different domains of DEPDC5 including DUF3608 [2, 3] , which also supports the idea that there could be other yet undiscovered functions of DEPDC5. Although mTOR activity has been associated with proper neuronal development [36] [37] [38] , this study shows that the neurodevelopmental role of DEPDC5 is mTOR independent. Hence, in addition to controlling neuronal development through mTOR, the components of the pathway might also have mTOR-independent roles.
Altogether, these results show a novel mTOR-independent effect of DEPDC5 on the GABAergic network that is very likely to be a key component of the DEPDC5-mediated focal epilepsy substratum. Indeed, abnormal wiring and functioning of the GABAergic system have been observed in epilepsy [39] , and GABA agonists have been used for decades alongside other drugs such as sodium and calcium channel blockers, glutamate blockers, carbonic anhydrase inhibitors, and other drugs as antiepileptics [40, 41] . Because GABA is the primary inhibitory neurotransmitter in the cortex, GABA agonists have long been considered the logical choice as anti-epileptic agents. However, in the emerging field of epilepsies caused by mutations in non-ion-channel genes, the contribution of the GABAergic network to epilepsy has not been studied, and this study shows that modulation of the GABAergic network together with targeting mTOR could be very effective against this class of non-ion channelopathies.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Routine zebrafish (Danio rerio) maintenance was performed following standard procedures (Westerfield) at 28.5 C under 12/12 hr light/dark cycles at the animal facility of the Centre Hospitalier de l'Universit e de Montr eal Research Centre (CRCHUM), Montr eal. All experiments were performed in compliance with the guidelines of the Canadian Council for Animal Care. The primary model used for this study was depdc5 loss of function mutants.
For generation of the depdc5 loss of function model, zebrafish optimized Cas9 mRNA was synthesized using the mMESSAGE mMACHINE SP6 kit (Ambion) and a pCS2-nCas9n template linearized with NotI. The following gRNA sequence targeting the 14 th exon of depdc5 was designed using the online tool CRISPRscan (PAM site is indicated in brackets): 5 0 -TGAGGATCATGAGC AAT(CGG)-3 0 . Synthesis of gRNA and of Cas9 mRNA was performed as described [42] . Briefly, a 52 nt oligo (sgRNA primer), containing the T7 promoter, the 20 nt of the specific sgRNA DNA binding sequence and a constant 15 nt tail for annealing, was used in combination with a 80 nt reverse oligo to add the sgRNA invariable 3 0 end (tail primer). A 117 bp PCR product was generated following these parameters: 3 min at 95 C, 30 cycles of 30 s at 95 C, 30 s at 45 C and 30 s at 72 C, and a final step at 72 C for 7 min. PCR products were purified using Qiaquick (QIAGEN) columns and approximately 120-150 ng of DNA were used as template for a T7 In vitro transcription (IVT) reaction (AmpliScribe-T7-Flash transcription kit from Epicenter). In vitro transcribed sgRNAs were DNase treated and precipitated with Sodium Acetate/Ethanol. Cas9 mRNA was in vitro transcribed from DNA linearized by XbaI using the mMachine T3 kit (Ambio). In vitro transcribed mRNAs were purified by phenol-chloroform followed by isopropanol precipitation.
Tubingen long fin (TL) wild-type embryos were collected for microinjection. A 1nL drop of a mix of 100 ng/mL of Cas9 mRNA and 30 ng/mL of gRNA was injected into one-cell stage embryos using a Picospritzer III pressure ejector.
Genotyping of depdc5+/+ (wild-type), +/À (heterozygous) and À/À (homozygous) animals was performed by high resolution melting analysis (HRM) using genomic DNA extracted by boiling the embryo/larva/clipped caudal fin in 50 mM NaOH for 10 min and then neutralizing it with 100 mM Tris HCl (pH 8). HRM primers were designed using the Universal Probe Library Assay Design Center (FP: 5 0 ATGCGCTGTTTGGTGAGG 3 0 and RP: 5 0 TCCAGGAGTGGGTGTTTTTG 3 0 ). All primer sets are available upon request. The PCR reactions were made with 5 mL of the Precision Melt Supermix for HRM analysis (Bio-Rad #172-5112), 0.5 mL of each primer (10 mM) and 2 mL of genomic DNA and water up to 10 mL. The PCR was performed in a LightCycler 480 Instrument II (Roche) using white 96-well plates. Two-step Evagreen PCR reaction protocol was 95 C for 2 min, then 45 cycles of 95 C for 10 s and 60 C for 30 s, followed by 95 C for 30 s, 60 C for 60 s, the temperature was increased by 0.02 C/sec until 95 C for 10 s, then cooling at 40 C. Curves were analyzed using the Roche LightCycler 480 software version 1.5.1.62.
In order to eliminate any putative off-target mutations, F0 founder was outcrossed with Tubingen long fin wild-type fish for at least three generations before phenotyping the embryos. All experiments were performed on larvae, and sex of zebrafish is not yet determined at this stage. depdc5+/À fish were incrossed to obtain depdc5+/+, +/À and À/À from the same cross for experiments. depdc5+/À fish of different generations have been used to verify consistency of the phenotype. 
METHOD DETAILS
In situ hybridization A specific probe for depdc5 corresponding to the 5 0 part of the coding sequence and first exon (971bp amplified with the following primers: FP: 5 0 TGACACAGAAAGTAGAGTTTGCAGG 3 0 ; RP: 5 0 GTTCTCAGCATCTTTGGGAGC 3 0 ) was cloned within the pCS2+ vector using TOPO TA cloning kit (Invitrogen). After sequencing, antisense probe was transcribed in vitro using SP6 RNA polymerase. Whole-mount in situ hybridization of zebrafish embryos was performed as described by Thisse and Thisse, 2008 [43] . Stained embryos were kept in 80% glycerol and imaged.
Western blotting
Larvae were anaesthetized and collected at 8 dpf, following which lysates were rapidly prepared by homogenization in high salt lysis buffer containing 10 mM Tris HCl (pH 8), 20% glycerol, 0.4 M KCl, protease and phosphatase inhibitors. After a freeze-thaw cycle to ensure efficient homogenization, the lysates were centrifuged at 13,000 rpm for 20 min. The supernatant was collected, and protein concentration was estimated using Bradford assay (Biorad). Western blotting was performed using 30 mg lysate per sample which were resolved on a 12% SDS-polyacrylamide gel. After electrophoresis, proteins on the gel were electrotransferred onto 0.22 micron nitrocellulose membrane. The membranes were blocked with 5% non-fat milk solution in 1X phosphate buffered saline or with 5% bovine serum albumin (Sigma) in 1X Tris buffered saline for immunoblotting with anti-g-tubulin (#T6557; Millipore Sigma) or anti-total S6 (2217; Cell Signaling Technologies) and anti-phospho S6 (#2215; Cell Signaling Technologies) respectively. Detection was performed using goat anti-mouse and goat anti-rabbit antibodies respectively conjugated with horse radish peroxidase. Bands were visualized with ECL and imaged using ChemiDoc (Biorad).
Non-invasive local field potential (LFP) recordings
Non-invasive recordings reading the electric signal from the head of the larvae were performed based on a modified protocol [19] . The larva was immobilized in 2% low melting point agarose (Invitrogen). Recording electrode (soda lime glass, Hilgenberg, Germany) was pulled with a DMZ Universal Puller (Zeitz, Germany) to a diameter of approximately 20 microns and filled with artificial cerebrospinal fluid (ACSF, 124 mM, NaCl, 2 mM KCl, 2 mM MgSO 4 , 2 mM CaCl 2 , 1.25 mM KH 2 PO 4 , 26 mM NaHCO 3 and 10 mM glucose). The differential signal between the recording electrode positioned on larva's head above the optic tectum and the reference electrode was amplified 10,000 times by DAGAN 2400 amplifier (Minnesota, USA), band pass filtered at 0.3-300 Hz and digitized at 2 kHz via a PCI-6251 interface (National Instruments, UK) with WinEDR (John Dempster, University of Strathclyde, UK). The duration of each recording was 10 min. Epileptiform events consisted of multispike bursts with amplitudes exceeding at least three times baseline and lasted for minimum 100 ms. Electrophysiological recordings were analyzed using Clampfit 10.2 software (Molecular Devices, USA).
Motor activity measurements 20 hpf embryos were embedded in low melting agarose and their movements inside the chorion were recorded using a camera for 20 min during which time they were kept hydrated. The Danioscope software (Noldus) was then used to quantify the percentage of time the embryos were active, the number of bursts and burst duration. At later stages (> 5dpf), larvae were transferred individually into a 96-well plate and activity was recorded over light-dark cycles using Basler GenIcam camera and DanioVision recording chamber (Noldus). Analysis was performed using the Ethovision XT 12 software (Noldus) to quantify the distance swam.
Drug treatment
Drugs were procured from Sigma-Aldrich and LC Laboratories and stock solutions were prepared (PTZ-300mM, GABA-100 mM, Muscimol-30 mM, Baclofen-15 mM, Vigabatrin-1M in water and rapamycin-500 mM in DMSO). Embryos were treated from 8 hpf unless mentioned otherwise. The water was replaced everyday with fresh water containing final concentration of the drug, till the activity measurement or end of the survival curve whichever was later. For PTZ assay, manually dechorionated 2 dpf embryos were placed in a 96-well plate and let accommodated for 20-30 min. PTZ from stock solution (300mM) was diluted to the final concentration (3mM) directly in the wells and the embryos were tracked immediately during 20 min using a Daniovision (Noldus).
Transcriptomic, differential expression and pathway analyses Three independent batches of 10 dpf depdc5+/+ and À/À larvae were dissected to extract the whole brain, by each of two experimenters, corresponding to experimental triplicates. Total RNA was extracted from these flash frozen brains using PicoPure RNA extraction kit (Thermo Fisher Scientific) following the manufacturer's standard protocol. For each sample, RNA extraction was made from 5 whole brains. Absence of contamination was assessed by Nanodrop using 260/280 and 260/230 ratios. Quality of total RNA was assessed with the BioAnalyzer Nano (Agilent) and all samples had a RIN above 9.
Library preparation was performed using the Truseq RNA (Illumina). 13 PCR cycles were required to amplify cDNA libraries. Libraries were quantified by Nanodrop and BioAnalyzer. All libraries were diluted to 10 nM and normalized with the Miseq SR50 v2. Libraries were pooled to equimolar concentration and multiplexed by 6 samples per lane. Sequencing was performed with the Illumina Hiseq2000 using the SBS Reagent Kit v3 (100 cycles, paired-end) with 1.6 nM of the pooled library. Cluster density was targeted at around 800k clusters/mm 2 . Between 45 and 55 million reads were generated for each sample. Library preparation and sequencing was done at the genomics platform of the Institute for Research in Immunology and Cancer (University of Montreal). About 90% of high quality reads were mapped onto the zv9 version of the zebrafish genome (ensemble release 77) using TopHat version 2.0.10. Differential gene expression analysis was assessed by DeSeq2 package using R software. Genes showing an absolute fold change > 1.4 and adjusted p value < 0.05 were considered to be significantly differentially expressed. Pathway analysis was performed using DAVID bioinformatics resources [44] . The list of differentially expressed genes was uploaded onto DAVID analysis wizard and a list of all expressed genes found in our dataset was used as a background for gene enrichment analysis.
QUANTIFICATION AND STATISTICAL ANALYSIS
Quantification of gephyrin-labeled puncta and GAD65/67-labeled neurofilaments Apotome images from 20 mm sections labeled with anti-gephyrin were deconvoluted using AutoQuant X (version X3.1.1) and processed using ImageJ (version 1.51 s). Z stacks were manually contrasted to maximize synaptic puncta visibility and reduce background noise. Using a semi-automatic macro, they were segmented by thresholding after filtering only synaptic puncta with diameters varying from 0.15 to 2 mm (macro written by Zsolt CSABA, INSERM UMR1141). For each image, the total number of gephyrin-positive synapse puncta was divided by the whole surface filled by these synapses to get the number of synapses per mm 2 . The ratios of a total number of images from three independent experiments (n (depdc5+/+) = 9; n(depdc5À/À) = 19) were averaged to get the means and standard errors of the means (SEM) and assess statistical tests between the two samples' groups.
For Gad65/67 quantification, 20 mm sections labeled with anti-GAD65/67 were imaged at zoom 6 using Leica HC PL APO CS 40X objective and processed using Bitplane Imaris (version 9.0.2). MeasurementPro's Filaments that detects automatically filament-like structures was used to outline and quantify the dendrites. Images from three independent experiments (n(depdc5+/+) = 3; n(depdc5À/À) = 3) were used to calculate the means and their standard errors (SEM) and assess statistical tests between the two groups.
Quantification of morphological and locomotion parameters was performed using Danioscope and Ethovision softwares respectively (Noldus) (described above). All data acquisition and quantification was performed by experimenter blind to the genotype of the larva. There is no evident morphological difference between depdc5+/+ and À/À which might bias the experimenter.
Details of biological and technical replicates, statistical test used and significance are mentioned in the corresponding figure legend. All experiments have been repeated thrice on an average (represented by N) and the number of animals per genotype used in each experiment is represented by n. In most instances, unpaired Student's t test was performed to estimate statistical significance. If p > 0.05, not significant, p % 0.05: *, p % 0.01: **, p % 0.001: *** and p % 0.0001:****
DATA AND SOFTWARE AVAILABILITY
Complete list of significantly up-and downregulated genes (p < 0.05) in depdc5À/À larval brains in comparison to depdc5+/+ brains is available in Table S1 . Complete list of genes overlapping between the depdc5 and gabra1 datasets is available in Table S2 . Table  S3 has a list of common genes between depdc5 and gabra1 datasets classified according to function. Table S4 gives the complete list of genes overlapping between depdc5 and tsc2 datasets.
